quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:18:39·85d
ANALYSTRating
REGENXBIO Inc. logo

Barclays resumed coverage on REGENXBIO with a new price target

RGNX· REGENXBIO Inc.
Health Care
Original source

Companies

  • RGNX
    REGENXBIO Inc.
    Health Care

Recent analyst ratings

  • Jan 28UpdateBarclays$37.00
  • Feb 11UpdateGoldman$14.00
  • Feb 7UpdateRaymond James$27.00
  • Nov 15UpdateMorgan Stanley$22.00
  • Oct 10UpdateRaymond James$18.00
  • Jun 7UpdateGoldman$38.00

Related

  • SEC9d
    SEC Form DEFA14A filed by REGENXBIO Inc.
  • SEC9d
    SEC Form DEF 14A filed by REGENXBIO Inc.
  • SEC20d
    SEC Form PRE 14A filed by REGENXBIO Inc.
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by REGENXBIO Inc.
  • SEC34d
    REGENXBIO Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
  • INSIDER42d
    Chief Medical Officer Pakola Steve sold $53,033 worth of shares (5,124 units at $10.35), decreasing direct ownership by 2% to 247,926 units (SEC Form 4)
  • PR43d
    REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
  • SEC49d
    SEC Form 10-K filed by REGENXBIO Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022